Across TCGA pan-cancer cohorts, DUSP3 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated DUSP3 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher DUSP3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DUSP3 expression acts as an unfavorable survival marker.
HNSC are the cancer types where DUSP3 Mutation most reproducibly stratifies survival.